Xinrong Chen, Kun Yang, Xingxia Zhang, Ka Li
Journal: European journal of clinical nutrition 2021;74(7):991-1000
PMID: 31371794
Whether it is beneficial to give preoperative oral nutritional supplements (P-ONS) to gastric cancer (GC) patients is still inconclusive. This study aimed to systematically explore the effectiveness and safety of P-ONS in GC patients. The PubMed, EMBASE, Medline, Cochrane Library, Chinese Biomedicine Literature Database (SinoMed), Chinese Scientific Journal Database (VIP), Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases were searched to identify relevant literature. A total of 11 randomized controlled trials (1183 patients) were included. Meta-analysis showed significantly lower levels of white blood cells (MD, -0.65; 95% CI, -1.01 to -0.30; P = 0.0003) and C-reactive protein (MD, -0.24; 95% CI, -0.31 to -0.16; P < 0.00001) in the P-ONS group than those in the routine diet group. Compared with the routine diet group, the P-ONS group had higher levels of albumin (MD, 1.63; 95% CI, 0.40-2.87; P = 0.010), IgG (MD, 0.65; 95% CI, 0.44-0.86; P < 0.00001), IgA (MD, 0.20; 95% CI, 0.02-0.37; P = 0.03), CD4 (MD, 2.02; 95% CI, 0.82-3.22; P = 0.001) and CD4/CD8 (MD, 0.07; 95% CI, 0.02-0.12; P = 0.008). However, there were no significant differences (P > 0.05) in terms of prealbumin (P = 0.08), IgM (P = 0.25), postoperative complications (P = 0.18), and body weight (P = 0.25) between the two groups. For gastric cancer patients with nutritional risk, preoperative oral nutritional supplements for 5-7 days may effectively reduce the postoperative inflammatory response, enhance immune function and improve the nutritional status of patients.
Medical:
Miscellaneous:
Research Materials:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.